previously described BCL6/IG translocations with a breakpoint in the 5 0 UTR of BCL6, or in the distant ABR. 2,6 Thus, in our cases BCL6 deregulation can not be explained by promoter substitution. In case no. 2 the inactivation of BCL6 negative autoregulation sites by mutations can be hypothesized, but in case no.1, for which no mutation was found inside these regions, the most reliable hypothesis involves cis-acting elements provided by the partner sequences. The expression of TMEM75, the closest locus brought by the translocation was investigated. The transcript was detected, at a level which did not differ significantly from the mean level of the 11 previous controls. Thus, the activation of BCL6 by TMEM75 regulating sequences remains possible, but the effects of more distant regions can not be precluded. Indeed, it was demonstrated that enhancers, defined as position and orientation independent activators of transcription, can exert regulating effects several hundred kilobases from targets by DNA folding, thus bringing together enhancer and the target. Regarding the pathophysiological role of the t(3;8), several hypotheses can be raised as: (i) BCL6 expression was significantly increased as compared to controls although the effects of mutations located in negatively regulating region could also explain the gene overexpression; (ii) we have shown previously that, in these cases MYC transcript was also overexpressed; (iii) the formation of MYC-BCL6 complexes at the protein level has been reported, 8 with an effect on MYC halflife, suppression of the synthesis of the p21 CIP cell cycle arrest gene, and inhibition of BCL6 acetylation. Therefore, the synergistic effect of MYC and BCL6 could explain the survival and clonal selection of a t(3;8) carrying cell in lymphoma progression.
Hematopoiesis is a tightly regulated multistage process. In the past decade, a number of transcription factors have been identified as crucial regulators in cell proliferation, differentiation and apoptosis in hematopoiesis. The proto-oncogene, LMO2 (also named rbtn2 or ttg2), is such a factor. LMO2 was first cloned from an acute T-lymphocyte leukemia (T-ALL) patient with a (11;14;p13;q11) translocation, 1 and subsequently showed crucial functions in hematopoiesis, as well as in angiogenesis.
2,3 LMO2 encodes a LIM-only protein comprised of two LIM domains characterized as a cysteine-rich motif consisting of two tandemly repeated zinc fingers and is considered to be a transcriptional regulator through the interactions with its partners, including LDB1 (CLIM2/NLI1), GATA1, TAL1(SCL) and E47, to form a multi-complex in which LMO2 functions as a bridging molecule with the two arms of GATA1 and TAL1/E47 bound to relevant DNA motifs. MicroRNAs (miRNAs) are a recently discovered class of small (E22-nt), non-coding RNAs that regulate gene expression via the RNA interference pathway either to promote degradation of the target mRNA or to repress its translation. There was increasing evidence showing that miRNAs had crucial functions in hematopoiesis, as well as leukemia (reviewed in Ref. 5). However, there were only a few reports about the expression profiles of miRNAs, and studies on miRNA expression regulations in hematopoiesis are limited. Until now, the best studied is miR-223, which has been shown to be regulated by C/EBPa 6 , PU.1 and GATA1. MiR-142, which was confirmed to have similar functions with miR-223 in promoting T-cell development, has rarely been studied before. In this study, we analyzed miR-142 expression profiles in the human erythroid/myeloid leukemia cell line, K562, the human T-cell lymphoblast-like cell line, Jurkat, and the Burkitt lymphoma cell line, Raji, by semi-quantitative RT-PCR. MiR-142 was detected in all these cell lines. We then analyzed LMO2 mRNA levels by semi-quantitative RT-PCR and LMO2 protein expression by immunoblot analysis in these cell lines. We found that LMO2 expression (both mRNA and protein) was absent in Jurkat cells, which expressed high levels of miR-142. In contrast, the other two cell lines that expressed high levels of LMO2 showed reduced miR-142 expression (Figure 1 ). These data suggested that there might be some relationship between miR-142 and LMO2.
To identify possible regulators of miR-142 expression, we cloned a 2320 bp region 5 0 flanking of pre-miR-142 from the human genome and then confirmed by sequencing, named N1 (À2320 to À1 bp). Then a set of 5 0 deletions were performed according to the restriction sites that were suitable for insertions to pGL4 vector and another two reporter constructs, named N2 (À1274 to À1 bp) and N3 (À1144 to À1 bp), were generated. These constructs were assayed in transient transfection experiments in K562 and control (HEK293) cell lines. All these reporters showed potent promoter activity in K562 cells, in which the miR-142 gene was endogenously expressed. However, the reporters were virtually silent in the control cell line. One notable thing was that the promoter activity was significantly increased when the À2320 to À1274 region was deleted. This indicated that this region might contain some repressor elements contributing to the regulating miR-142 expression in K562 cells (Figure 2b ). The putative binding sites for transcription factors were explored in this region using the Transcription Element Search System (URL: http://www.cbil.upenn.edu/tess). Notably, one putative GATA-binding site and an E-box (CACGTG) on the transcriptional minus strand were found. The distance between the E-box and the GATA site in this bipartite sequence was 9 bp, similar to the bipartite DNAbinding motif present in the promoter of several hematopoieticspecific genes found to be directly regulated by the LMO2 complex.
8 In addition, there were also two predicted transcriptional start sites in this region, as shown in Figure 2a (committed by NNPP Neural Network Promoter Prediction; http:// www.fruitfly.org/seq_tools/promoter.html), but they seemed to contribute with no prominent difference to the promoter activity (Figure 2b N2 and N3) .
To investigate whether LMO2 physically interacted with the miR-142 promoter region in vivo, we performed ChIP in K562 cells. Anti-LMO2 antibody, as well as anti-FLAG antibody used as a control, was used to immunoprecipitate the fragmented chromatin. After reversal of the crosslink, a segment of the miR-142 promoter (À2000 to À1703 bp, 298 bp) containing the E-box/GATA site was amplified by PCR using specific spanning primers. Primers recognizing the 3 0 -distal region were used as a negative control in the PCR reactions, as shown in Figure 3a . The result suggested that LMO2 could specifically bind to the À2000 to À1703 bp (298 bp) region of the miR-142 promoter (Figure 3b ), providing strong evidence that LMO2 was involved in the regulation of the miR-142 gene.
To further study, the regulatory effect of LMO2 on the miR142-promoter, we performed a LMO2 overexpression assay and knockdown assay using RNAi. The LMO2 siRNA construct (pSilencer4.1-siLMO2), or an unrelated control siRNA construct (pSilencer4.1-control), was transfected into K562 cells. LMO2 silencing efficiency was confirmed using western blot analysis and the results showed that the protein level was reduced to less than 20% (Figure 3b ). In the same cell lysates, we found a dramatic increase of N1 reporter activity compared to the cells transfected with control siRNA. Meanwhile, we also found that when overexpressing LMO2 in K562 cells, the reporter activity decreased by about 50% (Figure 3a) .
According to our data, LMO2 appeared to play a pivotal function in negatively regulating the expression of miR-142. Some reports pointed out that LMO2 functioned as a bridging MiR-142 expression was correlated with LMO2. (a) Expression levels of miR-142 and LMO2 were shown by reverse transcriptase (RT)-PCR analysis. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. The agarose gel electrophoresis data was quantified by UV Band scanning. Data represent three independent experiments. (b) LMO2 protein expression was detected by western blot analysis using monoclonal anti-LMO2 antibody.
Letters to the Editor molecule to assemble TAL1, LDB1, E47 and GATA1 to form a DNA-binding complex; and in the complex, GATA1 and TAL1 could bind to their relevant DNA motifs, while LMO2 itself was considered having no DNA-binding ability. 8 This reminded us that it probably also required the presence of GATA1, LDB1 and TAL1/E47, besides LMO2 to efficiently regulate the expression of miR-142. To investigate this question, we performed transactivation assays using K562 cells and the longest promoter reporter, N1, which contained the LMO2 complex-binding motif. Expression vectors for LMO2 and its partners, LDB1, GATA1, TAL1 and E47, were transfected separately or in combination to examine the function of these transcription factors on the promoter. The relative luciferase activity of single transfection with N1 reporter was marked as the control (100%). As shown in Figure 4c , co-transfection of the N1 reporter with the LDB1, TAL1 or E47 expression vector did not prominently affect the reporter activity, whereas overexpression of GATA1 conferred a slight inhibitory effect and overexpression of LMO2 inhibited the N1 reporter activity to a modest degree, similar to the result shown in Figure 4a . Notably, when we co-expressed Association of LMO2 with the hmiR-142 promoter was analyzed in vivo by CHIP analyses in K562 cells, using monoclonal antibody against LMO2 or unrelated Flag. The PCR was performed using a spanning primer to detect LMO2-binding and using crosslinked IP products as templates (lanes 4 and 6). Control primer was used as a negative control for PCR (lanes 3 and 5). PCR reactions with a spanning primer and a control primer using input K562 genomic DNA as the template were performed as the positive control of the PCR reaction (lanes 1 and 2).
LMO2 with GATA1, TAL1, LDB1 and E47, the N1 reporter activity was repressed remarkably to 20% compared to the control, showing a synergistic pattern of these members.
In addition, to detect the affect of LMO2 on endogenous miR-142 expression, we transiently transfected K562 cells with LMO2 expression vector alone, or the LMO2 complex including LMO2, GATA1, LDB1, TAL1 and E47 expression vectors, or the LMO2 siRNA construct, or the EGFP expression vector as a negative control. In cells overexpressing LMO2 or the LMO2 complex, the endogenous miR142 precursor expression levels were decreased significantly, whereas in the cells transfected with LMO2 siRNA construct, the miR142 precursor expression level showed a strong increase compared with the negative control (Figure 4d ). These data confirmed that LMO2, together with its co-factors, could negatively regulate the expression of miR-142 in vivo.
Previously, it was considered that the LMO2 complex customarily functioned by promoting the transcription of its target genes, and consequently upregulated a set of its downstream genes. 4, 8 We reported here that miRNA-142 was regulated by LMO2 together with its co-factors in a negative manner. This result indicated that the LMO2 complex could inhibit the expression of some genes directly. Considering the ability of miR-142 on promoting T-cell development and the differentiation arrest caused by abnormal expression of LMO2 in T-cell leukemia, our findings might partially explain the pathologic mechanism of LMO2 in T-cell leukemia, that is, LMO2 might exhibit its oncogenic property through inhibiting the expression of miR-142.
Recent studies described several miRNAs regulated by classic transcription factors. Our results showed that in hematopoiesis, miR-142 was also regulated by the transcriptional regulators, LMO2, LDB1, GATA1 and TAL1/E47, but in a negative manner.
Thus, LMO2 and its co-factors may also play crucial roles in hematopoiesis by regulating the expression levels of miRNAs.
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The non-isotopic RNase cleavage assay (NIRCA) works on the principle that RNase cleaves both strands of duplex RNA targets at mismatched bases and has been previously developed and validated as a method for screening for the presence of mutated p53 mRNA.
2 Briefly single stranded RNA is synthesized from opposing strands of patient PCR product and wild type control product, of the entire p53 coding region (from viral promoter sequences incorporated during PCR) and opposing RNA strands are hybridized. Subsequent digestion with RNase and analysis by agarose gel electrophoresis and ethidium bromide staining results in the observation of digested product for those samples containing a mismatch between patient and wild type sequence. We have used NIRCA to screen the entire coding region of the p53 gene from 480 patients diagnosed with a low-grade B-cell malignancy for p53 mutations (see Table 1 for disease classification).
The population of patients seen at our centre are very different from those seen at referral centres (where the majority of studies are carried out) and could be considered a more genuine representation of an unselected CLL population. In our patient population, 62.5% have never required treatment, 83% have stage A disease and many never require a follow up appointment. Our p53 mutation rate of 4% in CLL, although lower than many early studies, is in line with the only other study that we are aware of on a similar population of patients by Oscier et al.
(when patients specifically selected for inclusion due to known p53 mutation are excluded, an overall p53 mutation rate of 4% was found). 4 Many early studies did not benefit from the improved classification of patients that is now possible due to flow cytometric, cytogenetic and molecular biological techniques, resulting in inclusion of pathologies such as mantle cell lymphoma in leukaemic phase with CLL. When strict classification is applied the rate of cytogenetic abnormalities in CLL appears reduced.
3 Most studies report the rate of p53 abnormalities as a combination of deletion and mutation, the mutation rate alone is therefore lower than the 10-15% often quoted.
A total of 24 patients were found to have a p53 mutation and 23 of these mutations were in the DNA binding domain of the p53 gene (exons 5-8), suggesting that restricting screening to exons 5-8 in low-grade B-cell malignancies will not exclude detection of a large number of mutations. The aberrant mRNA present in the remaining patient (Patient 1) was missing exon 4 entirelyFthis could have arisen due to a splice site mutation, such mutations have been previously reported in CLL.
5 Studies over the years have reached different conclusions as to the distribution of p53 mutations in B-cell malignancies, few have screened the complete coding region of the gene. However Cordone et al.
6 reported 4/14 mutations to be outside of the evolutionary conserved region in direct contrast to our findings.
Trbusek et al. 7 recently published a study using a functional yeast assay in which they found 15/168 CLL patients to be p53 mutated; surprisingly, all of the mutations were different and only one affected a mutation hotspot codon for p53 mutation (codon 248). However, only 3/15 of their reported mutations did not affect codons with over 100 reported mutations on the UMD p53 mutation database.
8 In our present cohort of patients (Table 2) , 7/24 mutations affected the classic 'hotspot' codons 175, 248 and 273 with only 6 mutations that did not affect a commonly mutated codon.
8 Most studies report a similar distribution of p53 mutation in haematological malignancy. Two patients exhibited identical mutations at codon 248 which resulted in substitution of arginine by glycine rather than the commonly reported substitution by tryptophan or glutamine. There are reports of this mutation in the UMD p53 database in solid tumours (12 cases), Burkitts lymphoma (1 case), Diffuse Large B-cell lymphoma (1 case) and CLL (1 case) who is included in this study and in a previous report by this laboratory.
8 Although rare, this particular substitution results in almost complete abolition of p53 activity in common with the other recurrent mutations of this codon.
8 The mutation at codon 273 seen in two patients resulted in the frequently found arginine to histidine substitution. 
